An opinionated take on NEJM highlights for Q3 of 2026
- By Marc Herant
- NEJM
Payer studies of cheaper biologics, lentiviral in vivo CAR-Ts, new hope for COPD patients, base-editing PCSK-9, ADCs for SCLC, and the Rolls-Royce of data packages (or the holy grail?). Much to reflect on this quarter.